Literature DB >> 2184575

Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein.

X Y Ma1, K Sakai, F Sinangil, E Golub, D J Volsky.   

Abstract

Recently described noncytopathic human immunodeficiency viruses type-1 (HIV-1) form a new category within the HIV-1 family due to their unique biological properties and predominant occurrence in symptom-free individuals. To study the mechanism of noncytopathic HIV-1 infection, we compared the infectivity and life cycles of two closely related HIV-1 clones with noncytopathic (N1T-E) or cytopathic (N1T-A) properties. N1T-E virus exhibited slow kinetics of infection in T cells and monocytes. Slow infection was not due to defective virus entry, because N1T-E and N1T-A exhibited equally efficient virus-cell fusion activity and nucleocapsid internalization. Kinetic studies of N1T-E genome expression revealed low levels of viral RNA, structural proteins, and Tat protein during the first 7 days after virus entry. In contrast, cells infected with the same dose of cytopathic N1T-A virus began to express high levels of genomic RNA, structural proteins, and Tat protein within 48 hr of infection; the expression peaked on Day 5, followed by complete cell lysis. No delay in N1T-E replication, as compared to N1T-A, was observed after transfection of cloned N1T-E proviral DNA. N1T-E virus had intact Tat, Rev, and fusion functions and replicated well in chronically infected cells. These results suggest that delayed processing or expression of HIV-1 genome during the early phase of the virus replicative cycle is an important determinant in noncytopathic infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184575     DOI: 10.1016/0042-6822(90)90243-k

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Full-length CD4 electroinserted in the erythrocyte membrane as a long-lived inhibitor of infection by human immunodeficiency virus.

Authors:  M Zeira; P F Tosi; Y Mouneimne; J Lazarte; L Sneed; D J Volsky; C Nicolau
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication.

Authors:  M Kessler; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 3.  Guarding against the most dangerous emerging pathogens.

Authors:  P W Ewald
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

4.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

Authors:  X Y Ma; P Sova; W Chao; D J Volsky
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.

Authors:  J de Mareuil; B Brichacek; D Salaun; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity.

Authors:  K Sakai; X Y Ma; I Gordienko; D J Volsky
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.

Authors:  M Simm; M Shahabuddin; W Chao; J S Allan; D J Volsky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

Authors:  K Nagy; M Young; C Baboonian; J Merson; P Whittle; S Oroszlan
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.